Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

METTL14 overexpression identifies a biologically aggressive subgroup and correlates with adverse clinical outcomes in multiple myeloma

Liping Zuo, Zhixin Li, Qun Li, Chi Ma, Linyu Cai, Aoshuang Xu, Bo Zhang, Fengjuan Fan, Yuhuan Zheng, Chunyan Sun

Blood (2025) 146 (Supplement 1): 5774.

https://doi.org/10.1182/blood-2025-5774

Published: 2025

Journal Articles

Single-cell RNA sequencing reveals cellular heterogeneity and molecular features of extramedullary-involved multiple myeloma

yajun Wang, quande Lin, jiangxue Hou, xu Ji, Chunyan Sun, Yu Hu

Blood (2025) 146 (Supplement 1): 7472.

https://doi.org/10.1182/blood-2025-7472

Published: 2025

Journal Articles

Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results

Jian Xu, Jian Li, Yongqiang Wei, Weijun Fu, Bingzong Li, Xiu Li Sun, Kaini Shen, Xiaolei Wei, Lu Li, Liying Zhang, He Xu, Yueying Mao, Dehu Li, Aoshuang Xu, Fei Zhao, Chunyan Sun

Blood (2025) 146 (Supplement 1): 5828.

https://doi.org/10.1182/blood-2025-5828

Published: 2025

Journal Articles

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Blood (2025) 146 (Supplement 1): 5819.

https://doi.org/10.1182/blood-2025-5819

Published: 2025

Journal Articles

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Blood (2025) 146 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2025-5818

Published: 2025

Journal Articles

A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 91.

https://doi.org/10.1182/blood-2025-91

Published: 2025

Journal Articles

Systematic analysis of gene mutations in Chinese multiple myeloma patients.

Jinhua Wang, Hongxiao Han, Qun Li, Chi Ma, Hao Cai, Linyu Cai, Kaini Shen, Fei Zhao, Jian Xu, Lu Zhang, Bo Zhang, Jian Li, Chunyan Sun

Blood (2025) 146 (Supplement 1): 3989.

https://doi.org/10.1182/blood-2025-3989

Published: 2025

Journal Articles

Dynamic monitoring of circulating plasma cells in multiple myeloma: A Prospective multicenter study in China

Qun Li, Xiaojing Yan, Jian-Qing Mi, Aijun Liao, Bingzong Li, Hui-Han Wang, Huili Cai, Yafei Wang, Li Cai, Yu Hu, Chunyan Sun

Blood (2025) 146 (Supplement 1): 3984.

https://doi.org/10.1182/blood-2025-3984

Published: 2025

Journal Articles

DDX3X facilitates adaption to proteotoxic stress by regulating the translation of MAPKAPK2 and the stability of TMCO1 via stress granules in multiple myeloma

Fengjuan Fan, Shijun Jiang, Enqi Ni, Zhengyufan Wang, Yajun Wang, Liping Zuo, Chi Ma, Sonia Vallet, Aoshuang Xu, Jian Xu, Klaus Podar, Chunyan Sun, Yu Hu

Blood (2025) 146 (Supplement 1): 3944.

https://doi.org/10.1182/blood-2025-3944

Published: 2025

Journal Articles

Methionine promotes glycolysis and tumor progression in multiple myeloma by enhancing POU2AF1 expression via m⁶A modification

Chi Ma, Aoshuang Xu, Qun Li, Liping Zuo, Fengjuan Fan, Shanshan Luo, Jian Xu, Jian Li, Chunyan Sun

Blood (2025) 146 (Supplement 1): 5706.

https://doi.org/10.1182/blood-2025-5706

Published: 2025

Journal Articles

LDHAL6B promotes lactate-mediated histone H4K8 lactylation and enhances malignant cellular behaviors in multiple myeloma

Liping Zuo, Zhixin Li, Linyu Cai, Qun Li, Chi Ma, Dehu Li, Aoshuang Xu, Jian Xu, Fengjuan Fan, Yuhuan Zheng, Chunyan Sun

Blood (2025) 146 (Supplement 1): 2143.

https://doi.org/10.1182/blood-2025-2143

Published: 2025

Journal Articles

A retrospective study on orelabrutinib combined with anti-CD20 monoclonal antibody regimen in treating mucosa-associated lymphoid tissue lymphoma.

Hongyong Zhang, Zhipeng Cheng, Yingying Wu, Chunyan Sun, Danying Liao, Guohui Cui, Linghui Xia, Yu Hu, Heng Mei, Jun Fang

Blood (2025) 146 (Supplement 1): 7130.

https://doi.org/10.1182/blood-2025-7130

Published: 2025

Journal Articles

Teclistamab induced rapid and deep hematologic response in relapsed/refractory light chain amyloidosis: A multicenter retrospective study

Kaini Shen, Liye Zhong, Peilong Lai, Chunyan Sun, Donghua He, Ai Guan, Yi Xu, Jian Li

Blood (2025) 146 (Supplement 1): 7492.

https://doi.org/10.1182/blood-2025-7492

Published: 2025

Journal Articles

Quality of life in multiple myeloma: A scoping review

Aoshuang Xu, Han Yan, Qun Li, Sha Liu, Chunyan Sun, Yu Hu

Blood (2025) 146 (Supplement 1): 2807.

https://doi.org/10.1182/blood-2025-2807

Published: 2025

Journal Articles

Quantitative morphological parameters of bone marrow plasma cells are predictive of outcomes in plasma cell dyscrasias

Guangqi Wang, Hualong Zhao, Enmin Song, Hong Liu, Wanxin Chen, Jian Li, Zhangbo Chu, Chunyan Sun, Yu Hu

Blood (2025) 146 (Supplement 1): 5789.

https://doi.org/10.1182/blood-2025-5789

Published: 2025

Journal Articles

Automated subtype classification of acute leukemia from bone marrow smears using a cross-platform deep learning model

Guangqi Wang, Hualong Zhao, Enmin Song, Hong Liu, Wanxin Chen, Jian Li, Chunyan Sun, Zhangbo Chu, Yu Hu

Blood (2025) 146 (Supplement 1): 6128.

https://doi.org/10.1182/blood-2025-6128

Published: 2025

Journal Articles

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Blood (2024) 144 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2024-204513

Published: 2024

Journal Articles

Polymerase Theta Inhibition Impairs Tumor Growth and Enhances Melphalan-Induced DNA Damage in Multiple Myeloma

Qun Li, Chi Ma, Liping Zuo, Aoshuang Xu, Fei Zhao, Yu Hu, Chunyan Sun

Blood (2024) 144 (Supplement 1): 4659.

https://doi.org/10.1182/blood-2024-201184

Published: 2024

Journal Articles

A Retrospective Analysis of the Efficacy and Safety of Orelabrutinib-Containing Regimens in Marginal Zone Lymphoma

Hongyong Zhang, Zhipeng Cheng, Heng Mei, Chunyan Sun, Yingying Wu, Danying Liao, Fei Zhao, Yu Hu, Linghui Xia, Jun Fang

Blood (2024) 144 (Supplement 1): 6282.

https://doi.org/10.1182/blood-2024-198795

Published: 2024

Journal Articles

Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study

Kaini Shen, Ai Guan, Yu Wu, Chunyan Sun, Liye Zhong, Jun Luo, Jian Li

Blood (2024) 144 (Supplement 1): 893.

https://doi.org/10.1182/blood-2024-204346

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

METTL14 overexpression identifies a biologically aggressive subgroup and correlates with adverse clinical outcomes in multiple myeloma

Single-cell RNA sequencing reveals cellular heterogeneity and molecular features of extramedullary-involved multiple myeloma

Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma

Systematic analysis of gene mutations in Chinese multiple myeloma patients.

Dynamic monitoring of circulating plasma cells in multiple myeloma: A Prospective multicenter study in China

DDX3X facilitates adaption to proteotoxic stress by regulating the translation of MAPKAPK2 and the stability of TMCO1 via stress granules in multiple myeloma

Methionine promotes glycolysis and tumor progression in multiple myeloma by enhancing POU2AF1 expression via m⁶A modification

LDHAL6B promotes lactate-mediated histone H4K8 lactylation and enhances malignant cellular behaviors in multiple myeloma

A retrospective study on orelabrutinib combined with anti-CD20 monoclonal antibody regimen in treating mucosa-associated lymphoid tissue lymphoma.

Teclistamab induced rapid and deep hematologic response in relapsed/refractory light chain amyloidosis: A multicenter retrospective study

Quality of life in multiple myeloma: A scoping review

Quantitative morphological parameters of bone marrow plasma cells are predictive of outcomes in plasma cell dyscrasias

Automated subtype classification of acute leukemia from bone marrow smears using a cross-platform deep learning model

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Polymerase Theta Inhibition Impairs Tumor Growth and Enhances Melphalan-Induced DNA Damage in Multiple Myeloma

A Retrospective Analysis of the Efficacy and Safety of Orelabrutinib-Containing Regimens in Marginal Zone Lymphoma

Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only